Kornimate/medical-research-clean huggingface dataset:
neuromonitoring during rapid ventricular pacing in patients undergoing cerebral aneurysm surgery

Conditions: Cerebral Arterial Aneurysm; Ventricular Rate Response Pacing

Summary: to evaluate the effect of rapid ventricular pacing on the oxygenation of the brain in patients scheduled for cerebral aneurysm clipping surgery or arteriovenous malformation surgery.

patients scheduled for cerebral aneurysm clipping surgery or arteriovenous malformation surgery(asa 1to 3 over 18years) receive standard care general anesthesia including central venous line for rapid ventricular pacing technique. a contralateral foresight sensor is placed on the forehead of the patient at induction. after the craniotomy two micro electrodes(pbto2 and cerebral blood flow) are placed in the brain and fixated. a subdural strip electrode is placed on the surface of the brain to record the electrical activity. effect of mild hyperventilation and oxygenation with 100% o2 is evaluated.

Eligibility criteria:
inclusion criteria: * scheduled for cerebral aneurysm surgery or arterial venous malformation * american society of anesthesiologists classification 1, 2, or 3 exclusion criteria: * non
pediatric decentralization of art in south africa

Conditions: HIV/AIDS

Summary: the decentralization study will describe children taking antiretroviral therapy (art) at a larger health facility in the eastern cape province of south africa, between the years of 2004-2013. the study will be conducted at dora nginza hospital (dnh). the study will measure how many children stay in care and how many die, as well as their health status. the study will also compare whether children do better if they stay in care a large hospitals or if they get health care at smaller clinics. a second part of the study will find children in the community who have stopped coming for health care and find out what happened to them and what their health status is.

the investigators propose to conduct a two part study which will include a retrospective cohort study to examine care outcomes among pediatric patients 0-14 years of age initiated on antiretroviral therapy (art) in 2004-2013 at a larger peri-urban health facility in the eastern cape province of south africa. the study will be conducted at dora nginza hospital (dnh). the outcomes measured in the study will include retention and mortality, as well as virologic suppression rates for children initiated on art. in addition to reporting outcomes for all children with available data, the study will compare outcomes for children retained in care at dnh (where they initiated art) to those children who were referred out after initiation for routine follow-up at community health clinics and primary care clinics ("down referred"). a second part of the study will trace pediatric patients in the community who have been lost to follow-up (ltf) to ascertain their outcomes after they left care at the health facility.

Eligibility criteria:
art outcomes study: inclusion criteria: * hiv positive; less than 15 years of age; started art at dnh between 2004 and 2013. exclusion criteria: * anyone not meeting inclusion criteria tracing study: inclusion criteria: * legal caregiver (older than 18) a child who was included in the art outcomes study that was found to be ltfu from dnh or from the down-referral facility. exclusion criteria: * guardians who cannot be confirmed as the legal caregiver of the child

Keywords: antiretroviral therapy retention loss to follow up
a clinical trial of splinting for dequervain's tenosynovitis

Conditions: DeQuervain's Tenosynovitis

Summary: dequervain's tenosynovitis is characterized by pain on the pain on the radial (thumb) side of the wrist problems with thumb function. at this point, the standard care is to change daily activities, use a thumb brace, and the possible use of painkillers. there is a difference in opinion among physical therapists about how to use the splint in the treatment of dequervain tenosynovitis. some physicians tell patients to wear the brace at all times while other therapists encourage patients to exercise and use the brace as needed. both approaches to using the splint are accepted as standard. the purpose of this study is to test and evaluate these two ways of splinting and assess which one is better for patients with dequervain tenosynovitis.

de quervain's tenosynovitis (stenosing tenosynovitis of the first dorsal extensor compartment) is characterized by pain on the radial (thumb) side of the wrist and impairment of thumb and wrist function. histological evaluation is consistent with a chronic rather than an acute tenosynovitis consistent with the often prolonged course of this disease. nonoperative treatments include modification of activities, splint immobilization, icing and anti-inflammatory medication, and corticosteroid injections. long opponens splinting (or short arm thumb spica splinting; a splint that immobilizes the wrist and the thumb) is standard and well accepted. there is no consensus on the best protocol for use of the splint. some authors advocate full time splinting for 4 - 6 weeks, with the rationale that tendonitis will resolve with strict rest. other authors, perhaps aware of histological evidence that de quervain's is a chronic rather than acute inflammatory condition, feel that the splint serves merely to relieve symptoms and is best used as best suits each individual patient. to our knowledge, there are not data available regarding these disparate views. the ultimate prognosis for recovery in the condition seems satisfying, regardless of the treatment, and spontaneous recovery is the rule. psychological and personality factors, such as pain anxiety, catastrophizing, and depression are strongly related to upper extremity specific health status and may also influence recovery. the primary goal of this study is to determine which protocol of splinting leads to better outcome in non-surgical treatment of dequervain's tenosynovitis. as a secondary goal and to generate hypotheses for later studies we would like to evaluate the influence of psychosocial factors on both objective (grip strength) and subjective (dash questionnaire) measures of outcome.

Eligibility criteria:
inclusion criteria: * adult patient (age 18 years or greater) * physician very confident about the diagnosis of dequervain's tenosynovitis. exclusion criteria: * patients with previous history of surgical treatment for de quervain's. * skin conditions making splint wear problematic.

Keywords: dequervain's tenosynovitis splinting grip strength satisfaction dash questionnaire
effect of extracellular calcium on carbetocin mediated contractility in human myometrium

Conditions: Postpartum Hemorrhage (Primary)

Summary: postpartum hemorrhage (pph) continues to be an increasing problem globally. uterotonics play an essential role in the pharmacological management of uterine atony. carbetocin, a long acting analog of oxytocin has been recommended as a first line uterotonic for pph prophylaxis at cesarean delivery. considering many woman have associated comorbidities and are at high risk of pph, finding alternative pharmacological agents is essential. calcium is a key factor for myometrial contractions and calcium blood levels can be low at the end of pregnancy. both hypocalcemia and hypercalcemia could lead to a decrease in myometrial contractions. it is already been demonstrated that in both desensitized and naïve myometrium, normocalcemia provides a better uterine tone compared to hypo and hypercalcemia when oxytocin is given as the first uterotonic drug. currently, the role of extracelullar calcium in carbetocin- induced contractility is unknown. this will be the first ex vivo study to test the effects of extracellular calcium on oxytocin pretreated and naive myometrium. the results of this study will provide evidence on the use of this safe drug in clinical practice, particularly in women with labour arrest, and provide alternative pharmacological strategies to both prevention and treatment of pph, thus improving our clinical practice. the investigators hypothesize that extracellular normocalcemia would provide superior carbetocin-mediated contractility in both naive and oxytocin-pretreated myometrium compared with hypercalcemia and hypocalcemia.


Eligibility criteria:
inclusion criteria: * non-laboring women with gestational age between 37 to 41 weeks * not exposed to exogenous oxytocin, scheduled for a primary or first repeat cesarean delivery under neuraxial anesthesia. exclusion criteria: * patients requiring general anesthesia * more than 1 previous cesarean delivery * history of uterine atony * emergency cesarean section in labor * patients using medications that could affect myometrial contractility such as nifedipine, labetalol, or magnesium sulphate. * patients with any condition of predisposing to uterine atony and postpartum hemorrhage, such as abnormal placentation, multiple gestation, severe preeclampsia, macrosomia, polyhydroamnios, large uterine fibroids, chorioamnionitis, previous history of postpartum bleeding.

Keywords: carbetocin calcium uterine contraction cesarean delivery
effects of chest expansion exercises on thoracic expansion and vo2 max in children with chest burn

Conditions: Burns Multiple

Summary: burns are injuries to the skin or tissues caused by heat, electricity, chemicals, friction, or radiation. they can result from flames, hot solids, or liquids. in intensive care, physiotherapy often includes sitting exercises, passive motions, and active training, which are essential for recovery after burns. this study aims to evaluate the impact of chest expansion exercises using a stretch pole on chest expansion and vo2 max in children with chest burns. conducted as a quasi-experimental study at jinnah burn centre in lahore, it will involve 33 participants selected through non-probability convenience sampling. data collection will span six months. thoracic expansion will be measured with an inch tape, and vo2 max will be calculated using a specific formula. routine physiotherapy, including range of motion exercises and soft tissue massage, will be administered alongside chest expansion exercises for 20 minutes daily, five days a week, over three weeks.

burns are a kind of injury that can occur to the skin or other tissues. acute trauma can be brought on by heat, electricity, chemicals, friction, radiation, or other factors. burns are a kind of injury that can occur to the skin or other tissues. acute trauma can be brought on by heat, electricity, chemicals, friction, radiation, or other factors. burn are many types of burn flames (flame burns), hot solids (contact burns), or hot liquids (scalds). sitting out of bed, passive motions, and active/assisted exercises were frequent physiotherapy therapies in the intensive care unit. after a burn injury, exercise training serves as a significant and useful technique for achieving physical health. the objective of this study is to check the effect of chest expansion exercises by using stretch pole on chest expansion and vo2 max in children with chest burn. this study will be a quasi-experimental study .data will be collected from jinnah burn centre, lahore. data will be collected within 6 month from approval date of synopsis. sample size is 33. non-probability convenience sampling technique will be used in this study. thoracic expansion will be measured by inch tape and vo2 max will be calculated by using a formula. routine physiotherapy will be provided to the subjects routinely with chest expansion exercises. in routine physiotherapy, range of motion exercises, soft tissue massage, positioning to prevent the pressure sores will be provided for almost 20 minutes. the chest expansion exercises will be provided to the patients by using stretch pole for 20 minutes. all the interventions will be given to patients for 5 days in a week on daily basis for 3 weeks

Eligibility criteria:
inclusion criteria: * age: 5- 10 years. * children with mild to moderate chest burn. * children with decreased mobility due to chest burn. exclusion criteria: * chest burns with any post-burn complications, * neurological impairments, * contracture due to immobility, * infection due to chest burn.
dacomitinib treatment followed by 3rd generation egfr-tki in patients with egfr mutation positive advanced nsclc

Conditions: EGFR Activating Mutation; NSCLC Stage IV; NSCLC Stage IIIB; NSCLC, Recurrent

Summary: this is a non-interventional, multi-center, ambispective cohort study in real world to describe the effectiveness and safety profile in patients with egfr mutation-positive advanced nsclc treated with dacomitinib (vizimpro®) as the first-line treatment followed by 3rd generation egfr-tki in case the t790m resistance mutation was developed.

this is a multi-center observational study with both retrospective and prospective data collections to describe the effectiveness and safety of sequential dacomitinib and 3rd generation egfr-tki used in patients with egfr mutation-positive nsclc with t790m-aquired resistance in a clinical practice setting. the study will include patients who were or will be diagnosed as advanced nsclc with egfr mutation positive and received dacomitinib as first-line treatment followed by second-line 3rd generation egfr-tki treatment in multiple tertiary care hospitals after sep 1st, 2019. patients' clinical information prior to the study initiation in each hospital will be collected retrospectively through chart review. after the study initiation, new patient enrollment will last till dec 2022. patients' clinical care after the study initiation will be followed up prospectively until the end of study. the interval of response evaluation is recommended to be every 2 to 3 months in the treatment period and the interval of follow-up is recommended to be every 2 to 3 months in the post-treatment period till the end of study in the prospective data collection period.

Eligibility criteria:
inclusion criteria: * a confirmed diagnosis of locally advanced or metastatic nsclc. * the tumor harbored common egfr mutations (del19, l858r) at start of first-line treatment * age ≥ 18 years * had never received any egfr tki therapy. * patients that treated with dacomitinib (vizimpro®) as first-line treatment * confirmation of the t790m variant after first line dacomitinib treatment and receive any 3rd generation egfr-tki as second-line treatment. * asymptomatic cns metastases allowed * at least one lesion that can be accurately measured at baseline according to the recist 1.1, and which is suitable for accurate repeated measurements. * start second-line treatment with third generation egfr tki no later than 01 jan2023（\>10 month before data cutoff date） * all eligible patients are required to sign an informed consent before initiating the study exclusion criteria: * patients who received drug(s) other than 3rd generation egfr-tki as the second-line treatment and/or patients who received drug(s) other than dacomitinib (vizimpro®) as the first-line treatment * received or currently receiving dacomitinib from any interventional clinical trial
functionality of albumin in the context of hemodialysis

Conditions: Albumin; Dialysis; Redox State; Uremic; Toxemia

Summary: hemodialysis treatment enables patients with end-stage chronic kidney disease to survive. at the same time, however, this treatment also increases cardiovascular mortality, in particular due to a chronically increased level of inflammation and usually incomplete removal of uraemic toxins. both of these are closely linked with the functional properties of albumin. the aim of this study is to investigate the effects of various parameters of dialysis, in particular dialyzer properties and dialysis mode on the functional properties of albumin and to what extent these parameters can be used therapeutically, to improve the treatment quality of hemodialysis treatment in the long term by modifying albumin functional properties. our own preliminary work in this field and the current state of research indicate that, for example, the use of high-flux dialyzers can contribute to a reduction of the oxidative stress level. it also appears possible that treatment mode (haemodiafiltration instead of haemodialysis) may also have an effect on the binding and detoxification efficiency of albumin and thus on the removal of uraemic toxins. previous results have mostly been collected in observational studies. as a proof-of-concept study, this study will further investigate the concrete therapeutic applicability in an interventional study design.


Eligibility criteria:
inclusion criteria: * 18 years or older at least 3 month of hemodialysis treatment (3x/week) with constant dialysis treatment regimen exclusion criteria: * age ≤ 18 years * less than three months of regular (3x/week) hemodialysis treatments or less than 3 treatments/week * acute or chronic liver disease (child stage a or higher or fulfillment of the of the kings college criteria) * infusion of commercial human albumin (e.g. in the context of ascites drainage) in the last three months prior to study inclusion * acute or severe chronic infections * acute tumor disease
efficacy and safety of oral ibrexafungerp (scy-078) vs. placebo in subjects with acute vulvovaginal candidiasis (vanish 303)

Conditions: Candida Vulvovaginitis

Summary: this is a phase 3, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral ibrexafungerp (scy-078) compared to placebo in female subjects 12 years and older with avvc.

subjects who meet all of the inclusion and none of the exclusion criteria will be enrolled into the study and will be randomized in a 2:1 ratio to either oral ibrexafungerp or ibrexafungerp matching placebo, as follows: * oral ibrexafungerp 300-mg dose bid for 1 day * oral ibrexafungerp matching placebo bid for 1 day subjects will receive their first dose of study drug at the site and will be dispensed the second dose for self-administration at home 12 hours after the first dose. study blinding, randomization and stratification: this is a randomized, double-blind study. all site and sponsor personnel will be blinded to treatment assignment. approximately 366 eligible subjects will be enrolled and randomized in a 2:1 ratio to one of the two study treatment groups. for the purpose of maintaining treatment blinding, all subjects randomized to the placebo group will receive matching ibrexafungerp placebo tablets.

Eligibility criteria:
inclusion criteria: subject is a postmenarchal female subject 12 years and older subject has a diagnosis of symptomatic avvc at baseline including a positive microscopic examination with 10% koh in a vaginal sample revealing yeast forms (hyphae/pseudohyphae) or budding yeasts, and vaginal ph (≤4.5) exclusion criteria: subject has any vaginal condition other than avvc that may interfere with the diagnosis or evaluation of response to therapy, such as suspected or confirmed concurrent causes of vulvovaginitis and/or cervicitis (mixed infection) need for systemic and/or topical (vaginal) antifungal treatment, including prescription or over-the-counter products during the study and treatment for vvc 28 days prior to randomization subject is actively menstruating at the time of the baseline visit. subject has uncontrolled diabetes mellitus. subject has a vaginal sample with ph \>4.5. subject has a history of or an active cervical/vaginal cancer.
evaluation of neurocognitive performance in drug substituted patients under hepatitis c therapy

Conditions: Chronic Hepatitis C Infection

Summary: prospective, longitudinal multi-center study performed in 15 participating substitution centers in germany. aims: - primary objective: to compare the impact of the different substitution drugs (methadone, buprenorphine, and suboxone) on the neurocognitive, emotional, and quality-of-life-related tolerability in opioid dependent patients under hcv treatment. - secondary objective: to investigate if ifn therapy impairs efficacy (with respect to e.g. retention rates, concomitant drug use and in particular neurocognitive function) and tolerability of agonist maintenance treatment with methadone, buprenorphine, or suboxone


Eligibility criteria:
inclusion criteria: * opioid-dependent patients on current stable agonist maintenance therapy (for at least 6 months prior to study enrolment) with methadone, buprenorphine, or suboxone. * patients need to be infected with chronic hepatitis c and must have indication for therapy with peginterferon alfa and ribavirin. * patients with informed written consent with respect to a follow-up of psychiatric side effects and in particular neurocognitive performance. * patients with baseline monitoring of emotional state and neurocognitive performance. exclusion criteria: * according to spc * according to legal requirements reg. drug substitution therapy (btmvv) * insufficient knowledge of the german language or cognitive impairment (due to the indispensable application of questionnaires and the tap, test battery of attentional performance). * age under 18 years or over 65 years * coinfections such as hepatitis b virus or human immunodeficiency virus

Keywords: hepatitis c drug substitution neurocognitive patients with stable drug substitution therapy patients with interferon-based antiviral therapy
prevention of iph: electric warming mattress vs forced air warming blanket

Conditions: Inadvertent Perioperative Hypothermia; Patient Warming

Summary: this study will determine if modern under-patient warming mattresses are as effective as forced air warming blankets in preventing cold and shivering in patients scheduled for non emergency surgery.


Eligibility criteria:
inclusion criteria: * all patients undergoing elective (non emergency) surgery who will require intra-operative warming * patients whose surgery will be performed with them in the supine position exclusion criteria: * abdominal aortic aneurysm repair * all adults (over 18 years) who refuse,who are unable to fully understand the trial * all laparoscopic surgeries
efficacy of intermittent thetaburst stimulation compared to 10 hz stimulation on dorsolateral prefrontal cortex in treatment resistant major depressive disorder: a double-blind randomized study

Conditions: DEPRESSION

Summary: this trial will compare innovating stimulation parameters, intermittent theta burst stimulation, to the standard high frequency stimulation protocol. the left dorsolateral prefrontal cortex, targeted by mri navigation will be the site of stimulation in both treatment conditions. the study seeks to determine if there is a superiority in therapeutic efficacy with itbs protocol compared to conventional one.


Eligibility criteria:
inclusion criteria: * age 18 years to 75 years * both gender eligible * volontary and able to give consent * major depressive episode (madrs \> 20) single or recurrent * resistance to at least 2 antidepressants , * treated by antidepressant at efficient stable posology since more than 6 weeks exclusion criteria: * initiation or modification of antidepressant drug * neurodegenerative diseas * bipolar i, ii disorder * schizophrenia, schizoaffective disorder, schizophreniform, delusional disorder, or current psychotic symptoms * substance abuse in past 15 days * substance dependence not weaned * benzodiazepine and any anticonvulsant during rtms treatment course * ect failure in medical history * contra-indication to rtms and mri * pregnancy * difficulty to obtain informed consent